Saral Desai

Dr. Saral Desai

Psychiatry, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2022 in Psychiatry Research
Verified
Journal Article
Closed access
NDNishitha Depa
Nishitha Depa
Saral DesaiSaral Desai
Saral Desai
SPShweta Patel
Shweta Patel
SSSuraiya Silvi
Suraiya Silvi
SHSarah Hanif
Sarah Hanif
ZMZeeshan Mansuri
Zeeshan Mansuri

21 June 2021 in Cureus
Verified
Journal Article
Open access
Saral DesaiSaral Desai
Saral Desai
THTinu Hirachan
Tinu Hirachan
ATAnca Toma
Anca Toma
AGAdela Gerolemou
Adela Gerolemou
The clinical presentations of neuroleptic malignant syndrome (NMS) and malignant catatonia (MC) are similar, posing a diagnostic challenge. Here, we present a 58-year-old Caucasian male who presented to the emergency department with an altered mental state, fever, tachycardia, and rigidity. Labs were remarkable for elevated creatine phosphokinase (CPK) and leukocytosis. The patient was on a regimen of clozapine and cariprazine to manage schizophrenia, lorazepam to treat catatonia, and mirtazapine to treat insomnia and appetite stimulation. The patient was initially diagnosed with NMS after common metabolic, infectious, and substance-induced etiologies were ruled out. Within 72 hours of receiving dantrolene and lorazepam, the patient's fever, tachycardia, and other laboratory abnormalities resolved. However, when the patient's rigidity, waxy flexibility, mutism, and stupor persisted, the diagnosis was reconsidered and changed to MC. Our case discusses the overlapping clinical presentations of NMS and MC, demonstrating a diagnostic challenge.

23 November 2022 in Children
Verified
Journal Article
Open access
PDF file
Zeeshan FaruquiZeeshan Faruqui
Zeeshan Faruqui
ZTZalak Thakker
Zalak Thakker
DPDilshad Parveen
Dilshad Parveen
SNSaloni Naik
Saloni Naik
MUMarzhan Urazbayeva
Marzhan Urazbayeva
JKJagdeep Kaur
Jagdeep Kaur
Background: asthma, a chronic respiratory disease caused by inflammation and narrowing of the small airways in the lungs, is the most common chronic childhood disease. Prevalence of childhood asthma in the United States is 5.8%. In boys, prevalence is 5.7% and it is 6% in girls. Asthma is associated with other comorbidities such as major depressive disorder and anxiety disorder. This study explores the association between asthma and depression. Methods: we conducted a retrospective cross-sectional study using NHANES data from 2013 to 2018. Asthma and childhood onset asthma were assessed using questionnaires MCQ010 and MCQ025, respectively. Sociodemographic variables were summarized, and univariate analysis was performed to determine the association between asthma and major depressive disorder and its individual symptoms. Results: there were 402,167 participants from 2013–2018 in our study: no asthma in 84.70%; asthma in 15.30%. Childhood onset asthma (COA) included 10.51% and adult-onset asthma (AOA) included 4.79%. Median age of COA is 5 years and AOA is 41 years. Among the asthma groups, most AOA were females (67.77%, p < 0.0001), most COA were males (52.16%, p < 0.0001), and ethnicity was predominantly White in AOA (42.39%, p < 0001) and in COA (35.24%, p < 0.0001). AOA mostly had annual household income from $0–24,999 (35.91%, p < 0.0001), while COA mostly had annual household income from $25,000–64,999 (36.66%, p < 0.0001). There was a significantly higher prevalence of MDD in COA (38.90%) and AOA (47.30%) compared to NOA (31.91%). Frequency of symptoms related to MDD were found to have a significantly higher prevalence and severity in the asthma groups compared to no asthma, and slightly greater and more severe in AOA than in COA. Symptoms include having little interest in doing things (COA 18.38% vs. AOA 22.50% vs. NOA 15.44%), feeling down, depressed, or hopeless (COA 20.05% vs. AOA 22.77% vs. NOA 15.85%), having trouble sleeping or sleeping too much (COA 27.38% vs. AOA 23.15% vs. NOA 22.24%), feeling tired or having little energy (COA 39.17% vs. AOA 34.24% vs. NOA 33.97%), having poor appetite or overeating (COA 19.88% vs. AOA 20.02% vs. NOA 15.11%), feeling bad about yourself (COA 13.90% vs. AOA 13.79% vs. NOA 10.78%), having trouble concentrating on things (COA 12.34% vs. AOA 14.41% vs. NOA 10.06%), moving or speaking slowly or too fast (COA 8.59% vs. AOA 9.72% vs. NOA 6.09%), thinking you would be better off dead (COA 3.12% vs. AOA 4.38% vs. NOA 1.95%) and having the difficulties these problems have caused (COA 21.66% vs. AOA 26.73% vs. NOA 19.34%, p < 0.0001). Conclusion: MDD and related symptoms were significantly higher and more severe in participants with asthma compared to no asthma. Between adult-onset asthma compared to childhood onset asthma, adult-onset asthma had slightly greater and more severe MDD and related symptoms compared to childhood onset asthma.
1

1 October 2021 in World Journal of Oncology
Verified
Journal Article
Open access
PDF file
VBVal Bellman
Val Bellman
NRNina Russell
Nina Russell
KDKartik Depala
Kartik Depala
ADAlexandra Dellenbaugh
Alexandra Dellenbaugh
Saral DesaiSaral Desai
Saral Desai
SSSushma Srinivas
Sushma Srinivas
Challenges in Treating Cancer Patients With Unstable Psychiatric Disorder

26 September 2023 in The Primary Care Companion For CNS Disorders
Verified
Journal Article
Closed access
SPShweta Patel
Shweta Patel
SSSuraiya Silvi
Suraiya Silvi
Saral DesaiSaral Desai
Saral Desai
FRFayaz Rahman
Fayaz Rahman
NDNishitha Depa
Nishitha Depa
TPTapan Parikh
Tapan Parikh
In treatment-resistant depression, repetitive transcranial magnetic stimulation had higher odds of response and remission rates compared to sham.

12 September 2021 in Cureus
Verified
Journal Article
Open access
Saral DesaiSaral Desai
Saral Desai
BSBatool Sheikh
Batool Sheikh
LBLouis Belzie
Louis Belzie
Previous studies have suggested that some individuals experience neuropsychiatric symptoms following coronavirus disease 2019 (COVID-19) infection. We describe a case of new-onset psychosis following COVID-19 infection in a 55-year-old female with no prior psychiatric history. The patient started exhibiting symptoms of COVID-19 infection three weeks prior and was treated in the hospital with 4 L oxygen, dexamethasone 6 mg, and remdesivir therapy for seven days. Throughout her hospital stay, the patient had no neuropsychiatric symptoms. During her last week of stay, she was solely getting oxygen at home before presenting to the emergency department (ED) with severe psychosis. Her COVID-19 test in ED presentation was negative, and all potential etiologies for psychosis were ruled out. She was effectively treated for two weeks with 10 mg haloperidol and 1000 mg sodium valproate daily, followed by outpatient care. While variables such as a family history of bipolar disorder, psychosocial stressors, and steroid medication may have contributed to the patient's presentation, these circumstances alone did not result in neuropsychiatric symptoms in the past. COVID-19 infection may enhance the likelihood of developing neuropsychiatric problems on its own or amplify the effects of risk factors associated with an increased risk of psychosis. Neuropsychiatric consequences of COVID-19 infection may be under- or over-reported in individuals treated with steroids. Further research is necessary to identify individuals at risk of experiencing neuropsychiatric issues owing to COVID-19 infection and the prognosis.